Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 25 SEK 2.04% Market Closed
Market Cap: 867.8m SEK

EV/EBITDA
Enterprise Value to EBITDA

83.8
Current
20.2
Median
13
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
83.8
=
Enterprise Value
1.2B SEK
/
EBITDA
14.7m SEK
All Countries
Close
Market Cap EV/EBITDA
SE
Orexo AB
STO:ORX
862.6m SEK 83.8
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 35.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 16.6
CH
Roche Holding AG
SIX:ROG
252.3B CHF 11.5
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP 108
CH
Novartis AG
SIX:NOVN
202.4B CHF 11.2
US
Merck & Co Inc
NYSE:MRK
249.5B USD 9.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.6
IE
Endo International PLC
LSE:0Y5F
209B USD 331.1
US
Pfizer Inc
NYSE:PFE
147B USD 7.6
EBITDA Growth EV/EBITDA to Growth
SE
Orexo AB
STO:ORX
Average EV/EBITDA: 406.4
83.8
-15%
N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
hidden
2-Years Forward
EV/EBITDA
hidden
3-Years Forward
EV/EBITDA
hidden